Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trialCOVID-19 치료를 위한 아르테미시닌-피페라퀸의 안전성 및 효능: 공개, 비무작위 및 대조 시험Controlled Clinical Trial Published on 2021-01-012022-09-11 Journal: International journal of antimicrobial agents [Category] SARS, 임상, 치료법, 치료제, [키워드] 95% CI 95% confidence interval adverse events antimalarial Artemisinin both groups change changes Computed tomography control group Controlled trial coronavirus coronavirus disease coronavirus disease-2019 COVID-19 effective therapy Efficacy enrolled group laboratory parameter Mean ± standard deviation Mild Mild-to-moderate Open-label participant Patient percentage percentages physician Piperaquine Primary outcome QT interval respiratory Safety SARS-CoV-2 Secondary outcomes Severe acute respiratory syndrome severe acute respiratory syndrome-coronavirus-2 significantly shorter Standard deviation Treatment two groups undetectable Viral Viral RNA [DOI] 10.1016/j.ijantimicag.2020.106216 PMC 바로가기 [Article Type] Controlled Clinical Trial
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical TrialOriginal Article Published on 2021-01-012022-10-30 Journal: Iranian Journal of Pharmaceutical Research : IJPR [Category] COVID-19, [키워드] Admission Adverse reaction analyzed assigned Atazanavir clinical Clinical outcome clinical recovery clinical trial Coronavirus disease 2019 COVID-19 discharged double-blind Efficacy Efficacy and safety enrolled Frequency groups HCQ Hospital stay Hydroxychloroquine ICU ICU admission intensive care Intervention Intubated intubation Lopinavir Lopinavir/ritonavir median moderate Mortality nausea participant patients Primary outcome Randomized Randomly receive reduced reported Safety Secondary outcomes single dose statistically vomiting [DOI] 10.22037/ijpr.2021.115157.15243 PMC 바로가기 [Article Type] Original Article
De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?Review article Published on 2021-01-012022-10-05 Journal: Critical Reviews in Oncology/Hematology [Category] SARS, 치료법, [키워드] activated administration approach benefit Cancer cancer patient cancer treatment Care Chemotherapy clinical study Containment measure continuum COVID 19 De-escalation drug drugs Healthcare system high risk hospital identify Infection limit management Metronomic chemotherapy oral administration pandemic profiles public health reduce risk of infection Safety selected subgroup therapeutic strategy [DOI] 10.1016/j.critrevonc.2020.103148 [Article Type] Review article
Effectiveness and safety of lidocaine patch 5% to treat herpes zoster acute neuralgia and to prevent postherpetic neuralgia대상포진 급성 신경통 치료 및 후유증 신경통 예방을 위한 5% 리도카인 패치의 효과와 안전성Article Published on 2021-01-012023-05-31 Journal: Dermatologic therapy [Category] 대상포진, 두창, 수두, 홍역, [키워드] acute neuralgia Effectiveness herpes zoster lidocaine patch Postherpetic neuralgia Safety [DOI] 10.1111/dth.14590
Is there a role for childhood vaccination against COVID-19?Review Published on 2021-01-012023-07-12 Journal: Pediatric allergy and immunology : official public [Category] SARS, [키워드] childhood vaccination COVID-19 COVID-19 vaccines Efficacy Safety transmission of disease. [DOI] 10.1111/pai.13401 [Article Type] Review
COVID-19 and medical professionalism in a pandemicEditorial Published on 2021-01-012023-07-06 Journal: Postgraduate medical journal [Category] SARS, [키워드] health & health services administration & human resource management management MEDICAL EDUCATION & medical ethics quality in healthcare Safety training [DOI] 10.1136/postgradmedj-2020-138344 [Article Type] Editorial
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope ProteinHIV 서브타입 C DNA 및 MF59-보강 서브타입 C 엔벨로프 단백질의 안전성 및 면역원성을 평가하기 위한 1상 인간 면역결핍 바이러스(HIV) 백신 시험Articles and Commentaries Published on 2021-01-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] adjuvant administration advancement African Antibody Response antibody response rate Biojector boost CD4 cellular clinical Department DNA DNA prime/protein boost Efficacy elicited enrolled envelope envelope protein evaluate followed by glycoprotein greater healthy HIV HIV vaccine HIV-1 HIV-1 infection Human Human immunodeficiency virus Humoral response immunogenicity injected injection intramuscularly network partnership Phase 1 Placebo priming Protein Randomized regimen Registration registry response rate Result risk Safe Safety significantly significantly higher South South Africa subtype subtype C T-cell Response T-cell responses Trial vaccination Vaccine [DOI] 10.1093/cid/ciz1239 PMC 바로가기 [Article Type] Articles and Commentaries
Fighting on two fronts: drug-drug interactions in people living with HIV infected with SARS-CoV-2두 가지 전선에서의 싸움: SARS-CoV-2에 감염된 HIV에 감염된 사람들의 약물-약물 상호작용Article Published on 2021-01-012022-09-11 Journal: European Journal of Hospital Pharmacy [Category] 치료제, [키워드] Abstract AIDS clinical pharmacy drug-drug interaction Fighting Health health & HIV HIV & infected with SARS-CoV-2 Infectious diseases pharmacokinetics pharmacokinetics and dynamics. Safety with HIV [DOI] 10.1136/ejhpharm-2020-002390 PMC 바로가기 [Article Type] Article
Safety of secukinumab treatment in COVID-19 affected psoriatic patients코로나19 영향 건선 환자에서 세큐키누맙 치료 안전성Article Published on 2021-01-012022-09-12 Journal: Dermatologic therapy [Category] 진단, [키워드] affected COVID-19 Patient Safety Treatment [DOI] 10.1111/dth.14710 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial비활성화된 SARS-CoV-2 백신 BBIBP-CorV의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 1/2상 시험Clinical Trial Published on 2021-01-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단, [키워드] 95% CI accelerated acute respiratory syndrome Adverse reaction age antibody assigned BBIBP-CorV Beijing Block randomisation center China city Cohort concealed Control coronavirus COVID-19 pandemic creation District dose double-blind drug effort eight enrolled Fever geometric mean titre greater group Group allocation groups healthy humans Humoral response IgM/IgG inactivated Infectious diseases investigators Major Mild moderate neutralising antibody response neutralising antibody titre New Older outcome assessors participant Participants Placebo placebo-controlled plan post vaccination prevention Primary outcome Program randomised Randomly receive recipient recipients Registered reported Safe Safety SARS-CoV-2 SARS-CoV-2 vaccine Science secondary outcome separated Serious Adverse Event severity Shangqiu significantly stratified technology tested the placebo group the vaccine Tolerability Trial Vaccine vaccine candidate vaccine candidates [DOI] 10.1016/S1473-3099(20)30831-8 PMC 바로가기 [Article Type] Clinical Trial